According to sources familiar with the decision, Ms. Devlin was hired Oct. 15 and will report to the FDA’s chief of staff.
Her hire comes roughly two months after Mylan finalized a $465 million settlement with federal government over accusations the drugmaker improperly classified EpiPens as a generic drug to overcharge Medicaid.
More articles on supply chain:
Pharma’s lobbying efforts: 10 drugmakers that spent the most so far in 2017
FDA announces steps, new guidance to nurture medical device innovations: 4 things to know
FDA issues warning letter to Magellan over violations related to blood-lead tests
